In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvoseltamab, Regeneron talks about the possibility of linvoseltamab becoming a frontline ...
REGN-EB3 is a novel anti-viral antibody cocktail developed using the same rapid response technologies as REGN-COV2, Regeneron's investigational COVID-19 antibody cocktail "Developed using Regeneron's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback